Autonomix Medical, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.7M
- Price
- $3.41
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.73%
- Volume
- 56.7K
About
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Quick stats
Shares outstanding2.0M
Computed float1.8M
Float / shares92.2%
Cash runway (months)5.6
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001617867
Websitehttps://autonomix.com
AI Summary
AI-generated1/25
minorbullishother
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Autonomix Medical received Canadian Patent No. 3,183,802 covering its catheter-based transvascular technologies for accessing, guiding, and validating therapy delivery beyond the vessel wall.
The company's global IP portfolio now includes 112 issued or pending patent applications, with corresponding patents already issued in the United States and Europe and expirations extending into the late 2030s.
The grant strengthens the IP moat around a platform still investigational — initially developed for pancreatic cancer pain — and not yet cleared for marketing in the US.
Red flags
- technology is investigational and not cleared for marketing in the United States